Royalty Pharma plc Files 8-K Disclosing Positive Phase 3 Results for Daraxonrasib and Key Funding Developments

Key Highlights:

• Positive Phase 3 Results: Revolution Medicines, Inc. announced on April 13, 2026, positive Phase 3 results from the RASolute 302 trial for daraxonrasib, a novel oral RAS(ON) multi-selective inhibitor. The trial targeted patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had previously received treatment.
• Clinical Outcomes: The trial met all primary and key secondary endpoints, including progression-free survival and overall survival. Revolution Medicines intends to submit these data to global regulatory authorities, including the U.S. Food and Drug Administration (FDA), as part of a future New Drug Application under a Commissioner’s National Priority Voucher.
• Royalty Pharma Funding Agreement: In June 2025, Royalty Pharma entered into a \$2 billion funding agreement with Revolution Medicines. The deal consists of:
  • A synthetic royalty of up to \$1.25 billion on daraxonrasib.
  • A senior secured loan of up to \$750 million.
• Milestone Payments: Royalty Pharma funded \$250 million upfront and will provide another \$250 million upon FDA approval for daraxonrasib in metastatic PDAC.
• Royalty Structure: Should Revolution Medicines fully draw on the remaining \$750 million in synthetic royalty funding, Royalty Pharma’s royalty rates will be:
  • 7.80% on sales between \$0 and \$2 billion
  • 4.55% on sales between \$2 and \$4 billion
  • 2.40% on sales between \$4 and \$8 billion
• Senior Secured Loan: Royalty Pharma is also providing a senior secured term loan of up to \$750 million, disbursed in three tranches. The first \$250 million must be drawn following FDA approval, with the remaining tranches available based on achieving certain net sales milestones for daraxonrasib.

Potential Shareholder Impact

• Share Price Sensitivity: The announcement of positive Phase 3 results and the intention to submit for FDA approval is highly significant and likely to be price sensitive. Approval and commercialization of daraxonrasib could materially boost revenue streams for both Revolution Medicines and Royalty Pharma.
• Royalty Structure and Milestones: The structured royalty agreement and milestone-based loan tranches provide Royalty Pharma with exposure to a potentially blockbuster oncology asset. The royalty’s tiered structure ensures meaningful participation in future sales, which could positively impact Royalty Pharma’s financials and share valuation.
• Risk Factors: Investors should note that forward-looking statements are subject to risks and uncertainties, including regulatory approval, commercialization success, and market adoption of daraxonrasib.

Details Investors Must Know

• Regulatory Pathway: Submission to FDA under a National Priority Voucher could expedite regulatory review, potentially accelerating market entry and revenue realization.
• Financial Commitment: Royalty Pharma’s upfront and milestone-based funding, in combination with the synthetic royalty, represents a major commitment to Revolution Medicines and the daraxonrasib asset.
• Market Opportunity: Metastatic PDAC is an area of high unmet need, and daraxonrasib’s successful Phase 3 results position it as a significant new therapy in oncology.

Forward-Looking Statements Disclaimer

This article contains forward-looking statements as defined by the United States Private Securities Litigation Reform Act of 1995. Statements regarding Royalty Pharma’s strategies, financing plans, growth opportunities, and future events are based on current beliefs and assumptions and are subject to risks and uncertainties. Actual results may differ materially due to factors outside Royalty Pharma’s control, including regulatory decisions, commercialization success, and market conditions. The company does not undertake any obligation to update these statements except as required by law.

View Royalty Pharma plc Historical chart here